Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311331716> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4311331716 endingPage "S89" @default.
- W4311331716 startingPage "S89" @default.
- W4311331716 abstract "The introduction of the Novavax vaccine to the coronavirus disease 2019 (COVID-19) vaccine market has the potential to increase vaccine coverage in the United States (US), where coverage has lagged compared with other high-income countries. This modeling study estimated the cost-effectiveness of including the Novavax vaccine as a potential booster vaccine option for previously vaccinated adults in the US. A Markov model was developed to estimate COVID-19–related cases, hospitalizations, and deaths with and without the Novavax vaccine as a booster vaccine option. The model population included those boosted and those not boosted and was stratified by age, with health states including susceptible, detected infection, long COVID-19, and recovered. The severity of COVID-19 outcomes among detected infections was based on the highest level of care required. Booster vaccine efficacy was assumed to equal primary vaccine efficacy, sourced from published phase 3 clinical trials based primarily on the prototype variant. Efficacy was assumed to wane equally for all vaccines. Costs per dose were assumed to be equal for all booster vaccines. Other model parameters were sourced from published literature. We estimated the cost-effectiveness from a payer perspective (direct medical costs only) over a 1-year time horizon. Scenario analyses were conducted to investigate the impact of age, coverage assumptions, and analysis perspective on model outcomes. A 5% increase in booster vaccine coverage among a cohort of 100,000 adults eligible for booster vaccination, allocated to the Novavax vaccine market share, resulted in 20.00 quality-adjusted life-years (QALY) gained at an incremental cost of $2,082. The incremental cost-effectiveness ratio of adding the Novavax vaccine as a booster option was $104/QALY gained. Our results suggest that including the Novavax vaccine as a potential COVID-19 booster option for adults in the US has the potential to be cost-effective across a variety of coverage and market share scenarios." @default.
- W4311331716 created "2022-12-25" @default.
- W4311331716 creator A5000143281 @default.
- W4311331716 creator A5033440163 @default.
- W4311331716 creator A5039637335 @default.
- W4311331716 creator A5039663616 @default.
- W4311331716 creator A5065118684 @default.
- W4311331716 creator A5079079947 @default.
- W4311331716 date "2022-12-01" @default.
- W4311331716 modified "2023-09-23" @default.
- W4311331716 title "EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States" @default.
- W4311331716 doi "https://doi.org/10.1016/j.jval.2022.09.434" @default.
- W4311331716 hasPublicationYear "2022" @default.
- W4311331716 type Work @default.
- W4311331716 citedByCount "0" @default.
- W4311331716 crossrefType "journal-article" @default.
- W4311331716 hasAuthorship W4311331716A5000143281 @default.
- W4311331716 hasAuthorship W4311331716A5033440163 @default.
- W4311331716 hasAuthorship W4311331716A5039637335 @default.
- W4311331716 hasAuthorship W4311331716A5039663616 @default.
- W4311331716 hasAuthorship W4311331716A5065118684 @default.
- W4311331716 hasAuthorship W4311331716A5079079947 @default.
- W4311331716 hasBestOaLocation W43113317161 @default.
- W4311331716 hasConcept C112930515 @default.
- W4311331716 hasConcept C121332964 @default.
- W4311331716 hasConcept C12590561 @default.
- W4311331716 hasConcept C126322002 @default.
- W4311331716 hasConcept C1276947 @default.
- W4311331716 hasConcept C203014093 @default.
- W4311331716 hasConcept C203165030 @default.
- W4311331716 hasConcept C22070199 @default.
- W4311331716 hasConcept C2780441014 @default.
- W4311331716 hasConcept C2780664029 @default.
- W4311331716 hasConcept C2780801004 @default.
- W4311331716 hasConcept C2908647359 @default.
- W4311331716 hasConcept C3019080777 @default.
- W4311331716 hasConcept C515549039 @default.
- W4311331716 hasConcept C71924100 @default.
- W4311331716 hasConcept C72563966 @default.
- W4311331716 hasConcept C8891405 @default.
- W4311331716 hasConcept C99454951 @default.
- W4311331716 hasConceptScore W4311331716C112930515 @default.
- W4311331716 hasConceptScore W4311331716C121332964 @default.
- W4311331716 hasConceptScore W4311331716C12590561 @default.
- W4311331716 hasConceptScore W4311331716C126322002 @default.
- W4311331716 hasConceptScore W4311331716C1276947 @default.
- W4311331716 hasConceptScore W4311331716C203014093 @default.
- W4311331716 hasConceptScore W4311331716C203165030 @default.
- W4311331716 hasConceptScore W4311331716C22070199 @default.
- W4311331716 hasConceptScore W4311331716C2780441014 @default.
- W4311331716 hasConceptScore W4311331716C2780664029 @default.
- W4311331716 hasConceptScore W4311331716C2780801004 @default.
- W4311331716 hasConceptScore W4311331716C2908647359 @default.
- W4311331716 hasConceptScore W4311331716C3019080777 @default.
- W4311331716 hasConceptScore W4311331716C515549039 @default.
- W4311331716 hasConceptScore W4311331716C71924100 @default.
- W4311331716 hasConceptScore W4311331716C72563966 @default.
- W4311331716 hasConceptScore W4311331716C8891405 @default.
- W4311331716 hasConceptScore W4311331716C99454951 @default.
- W4311331716 hasIssue "12" @default.
- W4311331716 hasLocation W43113317161 @default.
- W4311331716 hasLocation W43113317162 @default.
- W4311331716 hasOpenAccess W4311331716 @default.
- W4311331716 hasPrimaryLocation W43113317161 @default.
- W4311331716 hasRelatedWork W2088587417 @default.
- W4311331716 hasRelatedWork W2165537129 @default.
- W4311331716 hasRelatedWork W2530938219 @default.
- W4311331716 hasRelatedWork W3216027958 @default.
- W4311331716 hasRelatedWork W4205534188 @default.
- W4311331716 hasRelatedWork W4205742435 @default.
- W4311331716 hasRelatedWork W4206046087 @default.
- W4311331716 hasRelatedWork W4283514472 @default.
- W4311331716 hasRelatedWork W4307547625 @default.
- W4311331716 hasRelatedWork W4363650745 @default.
- W4311331716 hasVolume "25" @default.
- W4311331716 isParatext "false" @default.
- W4311331716 isRetracted "false" @default.
- W4311331716 workType "article" @default.